Treatment with quercetin inhibits SARS-CoV-2 N protein-induced acute kidney injury by blocking Smad3-dependent G1 cell-cycle arrest
Wenjing Wu,Wenjing Wu,Wenjing Wu,Wenjing Wu,Wenbiao Wang,Liying Liang,Junzhe Chen,Junzhe Chen,Biao Wei,Xiao-Ru Huang,Xiao-Ru Huang,Xiaoqin Wang,Xiaoqin Wang,Xueqing Yu,Hui-Yao Lan,Hui-Yao Lan,Wenjing Wu,Wenbiao Wang,Liying Liang,Junzhe Chen,Biao Wei,Xiao-Ru Huang,Xiaoqin Wang,Xueqing Yu,Hui-Yao Lan
DOI: https://doi.org/10.1016/j.ymthe.2022.12.002
IF: 12.91
2023-02-01
Molecular Therapy
Abstract:Increasing evidence shows that SARS-CoV-2 can infect kidneys and cause acute kidney injury (AKI) in critically ill COVID-19 patients. However, mechanisms through which COVID-19 induces AKI are largely unknown, and treatment remains ineffective. Here, we report that kidney-specific overexpressing SARS-CoV-2 N gene can cause AKI, including tubular necrosis and elevated levels of serum creatinine and BUN in 8-week-old diabetic db/db mice, which become worse in those with older age (16 weeks) and underlying diabetic kidney disease (DKD). Treatment with quercetin, a purified product from traditional Chinese medicine (TCM) that shows effective treatment of COVID-19 patients, can significantly inhibit SARS-CoV-2 N protein-induced AKI in diabetic mice with or without underlying DKD. Mechanistically, quercetin can block the binding of SARS-CoV-2 N protein to Smad3, thereby inhibiting Smad3 signaling and Smad3-mediated cell death via the p16-dependent G1 cell-cycle arrest mechanism in vivo and in vitro. In conclusion, SARS-CoV-2 N protein is pathogenic and can cause severe AKI in diabetic mice, particularly in those with older age and pre-existing DKD, via the Smad3-dependent G1 cell-cycle arrest mechanism. Importantly, we identify that quercetin may be an effective TCM compound capable of inhibiting COVID-19 AKI by blocking SARS-CoV-2 N-Smad3-mediated cell death pathway.
genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology